- Home
- BGR vs LYEL Comparison
BGR vs LYEL Comparison
Compare BGR & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGR | LYEL |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.8M | 369.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BGR | LYEL |
|---|---|---|
| Price | $13.65 | $33.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 73.3K | 57.7K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.38 | $7.65 |
| 52 Week High | $13.37 | $35.16 |
Technical Indicators
Market Signals| Indicator | BGR | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 75.94 |
| Support Level | $13.73 | $20.59 |
| Resistance Level | $13.89 | $35.16 |
| Average True Range (ATR) | 0.22 | 2.56 |
| MACD | -0.02 | 1.05 |
| Stochastic Oscillator | 39.27 | 85.38 |
Price Performance
Historical ComparisonAbout BGR BlackRock Energy and Resources Trust
BlackRock Energy & Resources Trust is a closed-end equity fund providing total return through a combination of current income, gains and capital appreciation by investing in equity securities and derivatives of energy and natural resources companies. The fund invests in various sectors such as information technology, financials, healthcare, consumer discretionary, industrial, energy, materials and utilities.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.